Tetsuo Fujita1, Takefumi Satoh1, Terry L Timme2, Takahiro Hirayama3, Julie X Zhu4, Nobuyuki Kusaka1, Koji Naruishi1, Guang Yang3, Alexei Goltsov3, Jianxiang Wang3, Maria T Vlachaki5, Bin S Teh4, E Brian Butler4, Timothy C Thompson6. 1. Scott Department of Urology, Baylor College of Medicine, Houston, TX. 2. Scott Department of Urology, Baylor College of Medicine, Houston, TX; Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX. 3. Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. 4. Department of Radiology, Baylor College of Medicine, Houston, TX. 5. Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX; Department of Radiology, Baylor College of Medicine, Houston, TX. 6. Scott Department of Urology, Baylor College of Medicine, Houston, TX; Department of Radiology, Baylor College of Medicine, Houston, TX; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX. Electronic address: timthomp@mdanderson.org.
Abstract
OBJECTIVES: The objectives of this study are to explore the potential benefits of combining AdGlipr1 (or AdGLIPR1) gene therapy with radiotherapy using subcutaneous prostate and bladder cancer models. MATERIALS AND METHODS: Combination adenoviral vector-mediated gene therapy and radiotherapy were applied to 178-2 BMA and TSU-Pr1 cells in vitro and colony formation and apoptosis were analyzed. In addition, combination therapies were administered to mice bearing subcutaneous 178-2 BMA and TSU-Pr1 tumors, and tumor growth suppression and survival extension were compared with the monotherapies (AdGlipr1/AdGLIPR1 and radiotherapy) or control vector Adv/CMV/βgal, as well as single-cycle treatment with 2-cycle treatment. RESULTS: Combination treatment significantly suppressed colony formation and increased apoptosis in vitro. In vivo, combination therapy produced significant 178-2 BMA and TSU-Pr1 tumor growth suppression and survival extension compared with the monotherapies or the control. Further tumor growth suppression and survival extension were observed after 2 cycles of the combination treatment. CONCLUSIONS: Combining AdGlipr1 (AdGLIPR1) with radiotherapy may achieve additive or synergistic tumor control in selected prostate and bladder tumors, and additional therapeutic effects may result with repeated treatment cycles.
OBJECTIVES: The objectives of this study are to explore the potential benefits of combining AdGlipr1 (or AdGLIPR1) gene therapy with radiotherapy using subcutaneous prostate and bladder cancer models. MATERIALS AND METHODS: Combination adenoviral vector-mediated gene therapy and radiotherapy were applied to 178-2 BMA and TSU-Pr1 cells in vitro and colony formation and apoptosis were analyzed. In addition, combination therapies were administered to mice bearing subcutaneous 178-2 BMA and TSU-Pr1 tumors, and tumor growth suppression and survival extension were compared with the monotherapies (AdGlipr1/AdGLIPR1 and radiotherapy) or control vector Adv/CMV/βgal, as well as single-cycle treatment with 2-cycle treatment. RESULTS: Combination treatment significantly suppressed colony formation and increased apoptosis in vitro. In vivo, combination therapy produced significant 178-2 BMA and TSU-Pr1 tumor growth suppression and survival extension compared with the monotherapies or the control. Further tumor growth suppression and survival extension were observed after 2 cycles of the combination treatment. CONCLUSIONS: Combining AdGlipr1 (AdGLIPR1) with radiotherapy may achieve additive or synergistic tumor control in selected prostate and bladder tumors, and additional therapeutic effects may result with repeated treatment cycles.
Authors: R Sasaki; T Shirakawa; Z J Zhang; A Tamekane; A Matsumoto; K Sugimura; M Matsuo; S Kamidono; A Gotoh Journal: Int J Radiat Oncol Biol Phys Date: 2001-12-01 Impact factor: 7.038
Authors: Bin S Teh; Estuardo Aguilar-Cordova; Maria T Vlachaki; Laura Aguilar; Wei-Yuan Mai; James Caillouet; Maria Davis; Brian Miles; Dov Kadmon; Gustavo Ayala; Hsin H Lu; J Kam Chiu; L Steven Carpenter; Shiao Y Woo; Walter H Grant; Thomas Wheeler; Timothy C Thompson; E Brian Butler Journal: Oncologist Date: 2002
Authors: M R Shaker; G Yang; T L Timme; S H Park; D Kadmon; C Ren; X Ji; H M Lee; I Sehgal; M Anzano; M B Sporn; T C Thompson Journal: Clin Exp Metastasis Date: 2000 Impact factor: 5.150
Authors: B S Teh; E Aguilar-Cordova; K Kernen; C C Chou; M Shalev; M T Vlachaki; B Miles; D Kadmon; W Y Mai; J Caillouet; M Davis; G Ayala; T Wheeler; J Brady; L S Carpenter; H H Lu; J K Chiu; S Y Woo; T Thompson; E B Butler Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: Svend O Freytag; Dell Paielli; Mark Wing; Ken Rogulski; Steve Brown; Andy Kolozsvary; John Seely; Ken Barton; Alek Dragovic; Jae Ho Kim Journal: Int J Radiat Oncol Biol Phys Date: 2002-11-01 Impact factor: 7.038
Authors: Benjamin Goldsmith; Kai Tucker; Robert Greg Conway; Jiwei He; Thomas Guzzo; Justin Bekelman; Curtiland Deville; Neha Vapiwala; S Bruce Malkowicz; John Christodouleas Journal: Int J Radiat Oncol Biol Phys Date: 2012-07-03 Impact factor: 7.038
Authors: M T Vlachaki; M Chhikara; L Aguilar; X Zhu; K J Chiu; S Woo; B S Teh; T C Thompson; E B Butler; E Aguilar-Cordova Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-15 Impact factor: 7.038
Authors: Chengzhen Ren; Likun Li; Alexei A Goltsov; Terry L Timme; Salahaldin A Tahir; Jianxiang Wang; Laura Garza; A Craig Chinault; Timothy C Thompson Journal: Mol Cell Biol Date: 2002-05 Impact factor: 4.272
Authors: Kim E M van Kessel; Tahlita C M Zuiverloon; Arnout R Alberts; Joost L Boormans; Ellen C Zwarthoff Journal: Nat Rev Urol Date: 2015-09-22 Impact factor: 14.432
Authors: M Alizadeh Zarei; M A Takhshid; A Behzad Behbahani; S Y Hosseini; M A Okhovat; Gh R Rafiee Dehbidi; M A Mosleh Shirazi Journal: J Biomed Phys Eng Date: 2017-09-01
Authors: Jaíra Ferreira de Vasconcellos; Angelo Brunelli Albertoni Laranjeira; Paulo C Leal; Manoj K Bhasin; Priscila Pini Zenatti; Ricardo J Nunes; Rosendo A Yunes; Alexandre E Nowill; Towia A Libermann; Luiz Fernando Zerbini; José Andrés Yunes Journal: PLoS One Date: 2015-08-24 Impact factor: 3.240
Authors: Wael M Abdel-Rahman; Johanna E Lotsari-Salomaa; Sippy Kaur; Anni Niskakoski; Sakari Knuutila; Heikki Järvinen; Jukka-Pekka Mecklin; Päivi Peltomäki Journal: Gastroenterol Res Pract Date: 2016-03-07 Impact factor: 2.260